The 3D cardiac mapping system is a medical device used in electrophysiology procedures to create high-resolution 3D images of the heart anatomy and electrophysiology data. It helps physicians identify areas contributing to arrhythmias and guides them in effectively treating complex cardiac arrhythmias. The systems use advanced algorithms and sophisticated catheters fitted with multiple electrodes to record the electrical impulses in the heart and map activation patterns from inside the cardiac chambers. The recorded data is used to develop real-time 3D maps of the heart which enables electrophysiologists to accurately identify the location of arrhythmia and safely treat it through catheter ablation.
The 3D cardiac mapping system market is estimated to be valued at USD 1.628 Billion in 2024 and is expected to reach USD 2.890 Billion by 2031, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Key players in the 3D cardiac mapping system market include Biosense Webster, Abbott, Boston Scientific Corporation and Medtronic. Biosense Webster dominates the market with its CARTO 3 system that provides high-resolution 3D maps of cardiac anatomy and arrhythmia circuits. Abbott also has a significant market share through its EnSite Precision cardiac mapping and navigation system.
The demand for 3D Cardiac Mapping System Market is growing significantly owing to the rising prevalence of cardiovascular diseases and increasing adoption of catheter ablation procedures for treating arrhythmias. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. This is expected to drive the demand for advanced cardiac mapping and navigation technologies for effective diagnosis and treatment of cardiac arrhythmias.
Get more insights on: 3D Cardiac Mapping System Market